ALB and neoplasm: The PROSASH-II model, which comprised albumin, bilirubin, vascular invasion, extrahepatic spread, tumor size and AFP, has been shown to have good discriminative value in predicting the survival of patients with HCC receiving sorafenib treatment [15].